Jennifer S Herrick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2039654/publications.pdf

Version: 2024-02-01

201674 189892 2,680 62 27 50 citations g-index h-index papers 62 62 62 4449 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment. JAMA Network Open, 2022, 5, e2145319.	5.9	24
2	Exfoliation Syndrome in Baja Verapaz Guatemala: A Cross-Sectional Study and Review of the Literature. Journal of Clinical Medicine, 2022, 11, 1795.	2.4	3
3	Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow. JAMA Neurology, 2022, 79, 380.	9.0	26
4	Randomized evaluation of decision support interventions for atrial fibrillation: Rationale and design of the RED-AF study. American Heart Journal, 2022, 248, 42-52.	2.7	6
5	The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl. American Journal of Preventive Cardiology, 2022, 10, 100345.	3.0	4
6	Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors. JAMA Network Open, 2022, 5, e2220680.	5.9	3
7	Maternal cardiovascular complications at the time of delivery and subsequent re-hospitalization in the USA, 2010–16. European Heart Journal Quality of Care & Dutcomes, 2021, 7, 304-311.	4.0	3
8	Psychosocial aspects of health-related quality of life and the association with patient-reported bladder symptoms and satisfaction after spinal cord injury. Spinal Cord, 2021, 59, 987-996.	1.9	10
9	Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. Journal of the American Heart Association, 2021, 10, e019254.	3.7	11
10	Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events. Journal of the American College of Cardiology, 2021, 77, 1977-1990.	2.8	14
11	Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS ONE, 2021, 16, e0248080.	2.5	17
12	Long-Term Treatment Outcomes after Behavioral Speech Therapy for Chronic Refractory Cough. Lung, 2021, 199, 517-525.	3.3	16
13	Factors Associated with Antihypertensive Monotherapy Among US Adults with Treated Hypertension and Uncontrolled Blood Pressure Overall and by Race/Ethnicity, NHANES 2013-2018. American Heart Journal, 2021, , .	2.7	2
14	Sacubitril/Valsartan Initiation Among Veterans Who Are Reninâ€Angiotensinâ€Aldosterone System Inhibitor NaÃ-ve With Heart Failure and Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e020474.	3.7	1
15	Positive End-Expiratory Pressure and Respiratory Rate Modify the Association of Mechanical Power and Driving Pressure With Mortality Among Patients With Acute Respiratory Distress Syndrome., 2021, 3, e0583.		6
16	Reasons for cessation of clean intermittent catheterization after spinal cord injury: Results from the Neurogenic Bladder Research Group spinal cord injury registry. Neurourology and Urodynamics, 2020, 39, 211-219.	1.5	32
17	Mechanical power and driving pressure as predictors of mortality among patients with ARDS. Intensive Care Medicine, 2020, 46, 1941-1943.	8.2	37
18	Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005–2016. Hypertension, 2020, 75, 973-981.	2.7	72

#	Article	IF	CITATIONS
19	The p53-signaling pathway and colorectal cancer: Interactions between downstream p53 target genes and miRNAs. Genomics, 2019, 111, 762-771.	2.9	80
20	The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. Journal of Clinical Lipidology, 2019, 13, 754-761.	1.5	10
21	Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. Journal of the American Society of Nephrology: JASN, 2019, 30, 1756-1769.	6.1	71
22	Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT. Hypertension, 2019, 74, 267-275.	2.7	16
23	The MAPK-Signaling Pathway in Colorectal Cancer: Dysregulated Genes and Their Association With MicroRNAs. Cancer Informatics, 2018, 17, 117693511876652.	1.9	45
24	Mutation analysis of adenomas and carcinomas of the colon: Early and late drivers. Genes Chromosomes and Cancer, 2018, 57, 366-376.	2.8	50
25	Dysregulated genes and miRNAs in the apoptosis pathway in colorectal cancer patients. Apoptosis: an International Journal on Programmed Cell Death, 2018, 23, 237-250.	4.9	73
26	The PI3K/AKT signaling pathway: Associations of miRNAs with dysregulated gene expression in colorectal cancer. Molecular Carcinogenesis, 2018, 57, 243-261.	2.7	83
27	The NF-κB signalling pathway in colorectal cancer: associations between dysregulated gene and miRNA expression. Journal of Cancer Research and Clinical Oncology, 2018, 144, 269-283.	2.5	71
28	MicroRNAâ€transcription factor interactions and their combined effect on target gene expression in colon cancer cases. Genes Chromosomes and Cancer, 2018, 57, 192-202.	2.8	42
29	Power in pairs: assessing the statistical value of paired samples in tests for differential expression. BMC Genomics, 2018, 19, 953.	2.8	26
30	The $TGF\hat{l}^2$ -signaling pathway and colorectal cancer: associations between dysregulated genes and miRNAs. Journal of Translational Medicine, 2018, 16, 191.	4.4	35
31	miRNA involvement in cell cycle regulation in colorectal cancer cases. Genes and Cancer, 2018, 9, 53-65.	1.9	29
32	MicroRNA-messenger RNA interactions involving JAK-STAT signaling genes in colorectal cancer. Genes and Cancer, 2018, 9, 232-246.	1.9	6
33	Expression of Wnt-signaling pathway genes and their associations with miRNAs in colorectal cancer. Oncotarget, 2018, 9, 6075-6085.	1.8	17
34	Diet and lifestyle factors associated with miRNA expression in colorectal tissue. Pharmacogenomics and Personalized Medicine, 2017, Volume10, 1-16.	0.7	28
35	Infrequently expressed miRNAs in colorectal cancer tissue and tumor molecular phenotype. Modern Pathology, 2017, 30, 1152-1169.	5.5	17
36	Alterations in microRNA expression associated with alcohol consumption in rectal cancer subjects. Cancer Causes and Control, 2017, 28, 545-555.	1.8	7

#	Article	IF	CITATIONS
37	The miRNA landscape of colorectal polyps. Genes Chromosomes and Cancer, 2017, 56, 347-353.	2.8	8
38	Transcription factorâ€microRNA associations and their impact on colorectal cancer survival. Molecular Carcinogenesis, 2017, 56, 2512-2526.	2.7	13
39	The coâ€regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer. Genes Chromosomes and Cancer, 2017, 56, 769-787.	2.8	67
40	Single nucleotide polymorphisms within MicroRNAs, MicroRNA targets, and MicroRNA biogenesis genes and their impact on colorectal cancer survival. Genes Chromosomes and Cancer, 2017, 56, 285-295.	2.8	21
41	An Assessment of Database-Validated microRNA Target Genes in Normal Colonic Mucosa: Implications for Pathway Analysis. Cancer Informatics, 2017, 16, 117693511771640.	1.9	9
42	Genetic variants in the $TGF\hat{l}^2$ -signaling pathway influence expression of miRNAs in colon and rectal normal mucosa and tumor tissue. Oncotarget, 2017, 8, 16765-16783.	1.8	25
43	Identifying factors associated with the direction and significance of microRNA tumor-normal expression differences in colorectal cancer. BMC Cancer, 2017, 17, 707.	2.6	5
44	Infrequently expressed miRNAs influence survival after diagnosis with colorectal cancer. Oncotarget, 2017, 8, 83845-83859.	1.8	28
45	Colorectal tumor molecular phenotype and miRNA: expression profiles and prognosis. Modern Pathology, 2016, 29, 915-927.	5.5	41
46	Expression Profiles of miRNA Subsets Distinguish Human Colorectal Carcinoma and Normal Colonic Mucosa. Clinical and Translational Gastroenterology, 2016, 7, e152.	2.5	82
47	Association of cigarette smoking and microRNA expression in rectal cancer: Insight into tumor phenotype. Cancer Epidemiology, 2016, 45, 98-107.	1.9	36
48	Impact of polymorphisms in microRNA biogenesis genes on colon cancer risk and microRNA expression levels: a population-based, case-control study. BMC Medical Genomics, 2016, 9, 21.	1.5	33
49	MicroRNA profiles in colorectal carcinomas, adenomas and normal colonic mucosa: variations in miRNA expression and disease progression. Carcinogenesis, 2016, 37, 245-261.	2.8	107
50	MicroRNA Seed Region Length Impact on Target Messenger RNA Expression and Survival in Colorectal Cancer. PLoS ONE, 2016, 11, e0154177.	2.5	52
51	Telomere Length, TERT, and miRNA Expression. PLoS ONE, 2016, 11, e0162077.	2.5	14
52	Site-specific associations between miRNA expression and survival in colorectal cancer cases. Oncotarget, 2016, 7, 60193-60205.	1.8	41
53	Incorporation of subject-level covariates in quantile normalization of miRNA data. BMC Genomics, 2015, 16, 1045.	2.8	11
54	Gene expression in colon cancer: A focus on tumor site and molecular phenotype. Genes Chromosomes and Cancer, 2015, 54, 527-541.	2.8	39

#	Article	IF	CITATION
55	SNP Regulation of microRNA Expression and Subsequent Colon Cancer Risk. PLoS ONE, 2015, 10, e0143894.	2.5	25
56	Improved survival among colon cancer patients with increased differentially expressed pathways. BMC Medicine, 2015, 13, 75.	5.5	18
57	An evaluation and replication of mi <scp>RNA</scp> s with disease stage and colorectal cancerâ€specific mortality. International Journal of Cancer, 2015, 137, 428-438.	5.1	119
58	Accounting for Dependence Induced by Weighted KNN Imputation in Paired Samples, Motivated by a Colorectal Cancer Study. PLoS ONE, 2015, 10, e0119876.	2.5	27
59	Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study. Carcinogenesis, 2014, 35, 1750-1759.	2.8	39
60	Somatic alterations, metabolizing genes and smoking in rectal cancer. International Journal of Cancer, 2009, 125, 158-164.	5.1	48
61	Association of Smoking, CpG Island Methylator Phenotype, and V600E BRAF Mutations in Colon Cancer. Journal of the National Cancer Institute, 2006, 98, 1731-1738.	6.3	253
62	Evaluation of a Large, Population-Based Sample Supports a CpG Island Methylator Phenotype in Colon Cancer. Gastroenterology, 2005, 129, 837-845.	1.3	526